Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Roivant Sciences ( (ROIV) ) just unveiled an update.
Rakhi Kumar resigned from her roles as the Principal Accounting Officer of Roivant Sciences Ltd. and Chief Accounting Officer of its subsidiary, effective February 20, 2025. Jennifer Humes has been appointed as her successor, bringing extensive experience from JPMorgan Chase, Citigroup, and Deloitte. Her compensation package includes a base salary, sign-on bonus, and equity incentives, with specific vesting schedules.
More about Roivant Sciences
Roivant Sciences Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company’s market focus involves advancing healthcare solutions through its subsidiaries, targeting unmet medical needs.
YTD Price Performance: -11.26%
Average Trading Volume: 4,593,661
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.65B
For a thorough assessment of ROIV stock, go to TipRanks’ Stock Analysis page.
